New therapies for sarcoidosis

Clinical Pulmonary Medicine

Volumn 11, Issue 3, 2004, Pages 154-160

  Baughman, Robert P ^a,b   Lower, Elyse E ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Infliximab; Methotrexate; Thalidomide; Tumor necrosis factor

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; DOXYCYCLINE; HYDROXYCHLOROQUINE; IMMUNOMODULATING AGENT; INFLIXIMAB; METHOTREXATE; MINOCYCLINE; PENTOXIFYLLINE; PREDNISONE; THALIDOMIDE;

BLOOD TOXICITY; CARCINOGENICITY; CORTICOSTEROID THERAPY; CYSTITIS; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG RESPONSE; HEPATITIS; HUMAN; MUCOSA INFLAMMATION; NAUSEA; PNEUMONIA; REVIEW; SARCOIDOSIS; TERATOGENICITY; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

EID: 2542451980     PISSN: 10680640     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cpm.0000127199.76359.d8     Document Type: Review

References (76)

1. Baughman RP, du Bois RM, Lower EE. Sarcoidosis. Lancet. 2003;361:1111-1118.
2. Baughman RP, Shipley R, Eisentrout CE. Predictive value of gallium scan, angiotensin-converting enzyme level, and bronchoalveolar lavage in two-year follow-up of pulmonary sarcoidosis. Lung. 1987;165:371-377.
3. Rizzato G, Montemurro L, Colombo P. The late follow-up of chronic sarcoid patients previously treated with corticosteroids. Sarcoidosis. 1998;15:52-58.
4. Hunninghake GW, Gilbert S, Pueringer R, et al. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med. 1994;149:893-898.
5. Gottlieb JE, Israel HL, Steiner RM, et al. Outcome in sarcoidosis: the relationship of relapse to corticosteroid therapy. Chest. 1997;111:623-631.
6. Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med. 1983;208:525-533.
7. Johns CJ, Michele TM. The clinical management of sarcoidosis: a 50-year experience at the Johns Hopkins hospital. Medicine. 1999;78:65-111.
8. Baughman RP, Lower EE. Treatment of sarcoidosis with corticosteroids: who is going to relapse and why? Sarcoidosis. 1998;15:19-20.
9. Scadding JG. Prognosis of intrathoracic sarcoidosis in England. BMJ. 1961;4:1165-1172.
10. Nagai S, Shigematsu M, Hamada K, et al. Clinical courses and prognoses of pulmonary sarcoidosis. Curr Opin Pulm Med. 1999;5:293-298.
11. Baughman RP, Winget DB, Bowen EH, et al. Predicting respiratory failure in sarcoidosis patients. Sarcoidosis. 1997;14:154-158.
12. Bradley DA, Baughman RP, Raymond L, et al. Ocular manifestations of sarcoidosis. Sem Resp Crit Care Med. 2002;23:543-548.
13. Rizzato G, Colombo P. Nephrolithiasis as a presenting feature of chronic sarcoidosis: a prospective study. Sarcoidosis. 1996;13:167-172.
14. Zeitlin JF, Tami TA, Baughman R, et al. Nasal and sinus manifestations of sarcoidosis. Am J Rhinol. 2000;14:157-161.
15. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis: American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16:149-173.
16. Agbogu BN, Stem BJ, Sewell C, et al. Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol. 1995;52:875-879.
17. Zajicek JP, Scolding NJ, Foster O, et al. Central nervous system sarcoidosis: diagnosis and management. QJM. 1999;92:103-117.
18. Lower EE, Broderick JP, Brott TG, et al. Diagnosis and management of neurologic sarcoidosis. Arch Intern Med. 1997;157:1864-1868.
19. Baughman RP, Bradley DA, Raymond LA, et al. Double blind randomized trial of a tumor necrosis factor receptor antagonist (etanercept) for treatment of chronic ocular sarcoidosis. Am J Respir Crit Care Med. 2002;165:A495.
20. Baltzan M, Mehta S, Kirkham TH, et al. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med. 1999;160:192-197.
21. Baughman RP, Strohofer SA, Buchsbaum J, et al. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med. 1990;115:36-42.
22. Bost TW, Riches DW, Schumacher B, et al. Alveolar macrophages from patients with beryllium disease and sarcoidosis express increased levels of mRNA for tumor necrosis factor-alpha and interleukin-6 but not interleukin-1 beta. Am J Respir Cell Mol Biol. 1994;10:506-513.
23. Pueringer RJ, Schwartz DA, Dayton CS, et al. The relationship between alveolar macrophage TNF, IL-1, and PGE2 release, alveolitis, and disease severity in sarcoidosis. Chest. 1993;103:832-838.
24. Ziegenhagen MW, Rothe E, Zissel G, et al. Exagerated TNFalpha release of alveolar macrophages in corticosteroid resistent sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2002;19:185-190.
25. Martinet Y, Pinkston P, Saltini C, et al. Evaluation of the in vitro and in vivo effects of cyclosporine on the lung T-lymphocyte alveolitis of active pulmonary sarcoidosis. Am Rev Respir Dis. 1996;138:1242-1248.
26. Wyser CP, van Schalkwyk EM, Alheit B, et al. Treatment of progressive pulmonary sarcoidosis with cyclosporin A: a randomized controlled trial. Am J Respir Crit Care Med. 1997;156:1571-1576.
27. Lower EE, Smith JT, Martelo OJ, et al. The anemia of sarcoidosis. Sarcoidosis. 1988;5:51-55.
28. Browne PM, Sharma OP, Salkin D. Bone marrow sarcoidosis. JAMA. 1978;240:43-50.
29. Baughman RP, Lower EE. Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis. Chest. 1992;102:1090-1094.
30. Baughman RP, Lower EE. A clinical approach to the use of methotrexate for sarcoidosis. Thorax. 1999;54:742-746.
31. Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis. 2000;17:60-66.
32. Lynch JPI, McCune WJ. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am J Respir Crit Care Med. 1997;155:395-420.
33. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164:1885-1889.
34. Lower EE, Blau R, Gazder P, et al. The risk of premature menopause induced by chemotherapy for early breast cancer. J Womens Health Gend Based Med. 1999;8:949-954.
35. Lloyd ME, Carr M, McElhatton P, et al. The effects of methotrexate on pregnancy, fertility and lactation. QJM. 1999;92:551-563.
36. Bar J, Stahl B, Hod M, et al. Is immunosuppression therapy in renal allograft recipients teratogenic? a single-center experience. Am J Med Genet. 2003;116A:31-36.
37. Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med. 1996;124:477-484.
38. Confavreux C, Saddier P, Grimaud J, et al. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology. 1996;46:1607-1612.
39. Lamers CB, Griffioen G, Van HR, et al. Azathioprine: an update on clinical efficacy and safety in inflammatory bowel disease. Scand J Gastroenterol. 1999;230:111-115.
40. Zisman DA, McCune WJ, Tino G, et al. Drug-induced pneumonitis: the role of methotrexate. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18:243-252.
41. Baughman RP, Koehler A, Bejarano PA, et al. Role of liver function tests in detecting methotrexate-induced liver damage in sarcoidosis. Arch Intern Med. 2003;163:615-620.
42. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor-alpha neutralizing agent. N Engl J Med. 2001;345:1098-1104.
43. Baughman RP, Ohmichi M, Lower EE. Combination therapy for sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18:133-137.
44. Kavanaugh A, Clair EW, McCune WJ, et al. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol. 2000;27:841-850.
45. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18:70-74.
46. Siltzbach LE, Teirstein AS. Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis. Acta Med Scand. 1964;425:302S-308S.
47. British Tuberculosis Association. Chloroquine in the treatment of sarcoidosis. Tubercle. 1967;48:257-272.
48. Sharma OP. Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurologic involvement. Arch Neurol. 1998;55:1248-1254.
49. Adams JS, Diz MM, Sharma OP. Effective reduction in the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia with short-course chloroquine therapy. Ann Intern Med. 1989;111:437-438.
50. Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med. 1995;155:846-851.
51. Vucinic VM. What is the future of methotrexate in sarcoidosis? a study and review. Curr Opin Pulm Med. 2002;8:470-476.
52. Webster GF, Razsi LK, Sanchez M, et al. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J Am Acad Dermatol. 1991;24:451-454.
53. Dev S, McCallum RM, Jaffe GJ. Methotrexate for sarcoid-associated panuveitis. Ophthalmology. 1999;106:111-118.
54. Gedalia A, Molina JF, Ellis GS, et al. Low-dose methotrexate therapy for childhood sarcoidosis. J Pediatr. 1997;130:25-29.
55. Fenton DA, Shaw M, Black MN. Invasive nasal sarcoidosis treated with methotrexate. Clin Exp Dermatol. 1985;10:279-283.
56. Muller-Quernheim J, Kienast K, Held M, et al. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J. 1999;14:1117-1122.
57. Sharma OP, Hughes DTD, James DG, et al. Immunosuppressive therapy with azathioprine in sarcoidosis. 1971;635-637.
58. Stem BJ, Schonfeld SA, Sewell C, et al. The treatment of neurosarcoidosis with cyclosporine. Arch Neurol. 1992;49:1065-1072.
59. Baughman RP, Judson MA, Teirstein AS, et al. Thalidomide for chronic sarcoidosis. Chest. 2002;122:227-232.
60. Carlesimo M, Giustini S, Rossi A, et al. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol. 1995;32:866-869.
61. Oliver SJ, Kikuchi T, Kruege JG, et al. Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement. Clin Immunol. 2002;102:225-236.
62. Mallbris L, Ljungberg A, Hedblad MA, et al. Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-alpha therapy. J Am Acad Dermatol. 2003;48:290-293.
63. Pettersen JA, Zochodne DW, Bell RB, et al. Refractory neurosarcoidosis responding to infliximab. Neurology. 2002;59:1660-1661.
64. Yee AMF, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis-alpha therapy. Ann Intern Med. 2001;135:27-31.
65. Bachelez H, Senet P, Cadranel J, et al. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol. 2001;137:69-73.
66. Zabel P, Entzian P, Dalhoff K, et al. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med. 1997;155:1665-1669.
67. Kang S, Suh JH. Radiation therapy for neurosarcoidosis: report of three cases from a single institution. Radiat Oncol Investig. 1999;7:309-312.
68. Demeter SL. Myocardial sarcoidosis unresponsive to steroids: treatment with cyclophosphamide. Chest. 1988;94:202-203.
69. Kataria YP. Chlorambucil in sarcoidosis. Chest. 1980;78:36-42.
70. Baughman RP, Lower EE. The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis. Am Rev Respir Dis. 1990;142:1268-1271.
71. Gibson GJ, Prescott RJ, Muers MF, et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax. 1996;51:238-247.
72. Paramothayan S, Jones PW. Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA. 2002;287:1301-1307.
73. Marques LJ, Zheng L, Poulakis N, et al. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med. 1999;159:508-511.
74. Muller-Quernheim J, Kienast K, Held M, et al. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J. 1999;14:1117-1122.
75. Muller-Quernheim J, Kienast K, Held M, et al. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J. 1999;14:1117-1122.
76. Tavares JL, Wangoo A, Dilworth P, et al. Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages. Respir Med. 1997;91:31-39.